Patients With Unilateral Peripheral Vestibular Deficits Clinical Trial
— VRVESTOfficial title:
Realitat Virtual Com a Tractament Coadjuvant en rehabilitació Vestibular
Vertigo / dizziness, imbalance and other symptoms related to vestibular pathology have a life prevalence of 7.4%. Peripheral and unilateral vestibulopathy are among the most common types, and in some patients the symptoms become chronic and disabling, which makes it difficult for them to lead a normal life and has a significant socio-economic impact. In recent years, the effect of vestibular rehabilitation with virtual reality has been studied and positive results have been obtained when compared with traditional rehabilitation, but despite rehabilitation there is patients who are still chronic, and the reasons for this prognostic variability are still unknown and require further treatment. Virtual reality-based stimulation can play a significant role as an adjunct to conventional vestibular rehabilitation, improving its effectiveness.
| Status | Recruiting |
| Enrollment | 20 |
| Est. completion date | March 1, 2021 |
| Est. primary completion date | January 1, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Unilateral vestibular deficit - Vestibular neuritis - Sudden hearing loss with vestibular involvement - Labyrinthitis - Ménière's disease - Vestibular Shwannoma - Benign paroxysmal positional vertigo - Vestibular symptoms (vertigo, dizziness, imbalance, gait instability, kinosis and / or oscillopsy) chronic (more than 6 weeks of evolution) - Over 18 years old Exclusion Criteria: - Failure to meet some of the inclusion criteria - Neurological, traumatological, rheumatological, ophthalmological or systemic pathology that may interfere with the balance - Inability to understand participation in the study - Non-acceptance to participate in the study |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Hospital Universitari de Tarragona Joan XXIII | Tarragona |
| Lead Sponsor | Collaborator |
|---|---|
| Universitat Pompeu Fabra |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change pre-post treatment in the Dizziness handicap inventory (DHI) (0-100) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in Posturography (Wii+software RombergLab) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in Test up and go (TUG) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in Berg Scale (0-56) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in Tinneti Test (1-28) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in Simulator Sickness Questionnaire (SSQ) (0-14) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in the Video-head impulse test (vHIT) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in the Barthel Index (0-100) | Change within subjects from baseline to the end of week 4 | 4 weeks | |
| Secondary | Change pre-post treatment in the SF 12 Test (0-100) | Change within subjects from baseline to the end of week 4 | 4 weeks |